Inspira Technologies OXY B.H.N. (IINN) Expected to Announce Earnings on Wednesday

Posted by ABMN Staff on Mar 25th, 2026

Inspira Technologies OXY B.H.N. (NASDAQ:IINN – Get Free Report) is projected to issue its resultson Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $0.20 million for the quarter.

Inspira Technologies OXY B.H.N. Trading Down 3.1%

Shares of NASDAQ:IINN opened at $0.55 on Wednesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.15. The firm has a fifty day moving average price of $0.66 and a 200 day moving average price of $0.93. Inspira Technologies OXY B.H.N. has a fifty-two week low of $0.40 and a fifty-two week high of $1.65.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inspira Technologies OXY B.H.N. in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $2.00.

Read Our Latest Analysis on Inspira Technologies OXY B.H.N.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inspira Technologies OXY B.H.N. stock. Citadel Advisors LLC purchased a new position in Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 82,567 shares of the company’s stock, valued at approximately $105,000. Citadel Advisors LLC owned about 0.65% of Inspira Technologies OXY B.H.N. as of its most recent filing with the Securities and Exchange Commission (SEC). 12.72% of the stock is currently owned by hedge funds and other institutional investors.

Inspira Technologies OXY B.H.N. Company Profile

(Get Free Report)

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.